BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SCTB14 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SCTB14\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07362459-2721@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SCTB14: Phase 3 readout est. (NCT07362459)
DESCRIPTION:SCTB14\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in
  Non-Small Cell Lung Cancer.\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07362459
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06304818-2721@assetmemo.bio
DTSTAMP:20261121T004544Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:SCTB14: Phase 1/2 readout est. (NCT06304818)
DESCRIPTION:SCTB14\, phase 1/2.\nStudy: Aims to Explore the Safety\, Tolera
 bility\, and Preliminary Efficacy of SCTB14 in Adult Patients With Advance
 d Malignant Solid Tumours.\nEstimated primary completion: 30 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06304818
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
